Methotrexate and Mycophenolate Mofetil for UVEITIS
Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the
investigators propose to establish which immunosuppressive therapy, methotrexate or
mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for
the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative
effectiveness trial.